ArticleAnnals of clinical and translational neurology2025
Plasma Glial Fibrillary Acidic Protein Correlates With Brain Metal Burden in Wilson's Disease.
Article in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Voxel-Wise Whole-Brain Analysis in Quantitative Susceptibility Mapping: A Narrative Review.Human brain mapping · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveNeuroinflammation driven by extracellular copper contributes to neuronal damage in Wilson's disease (WD). This study investigated the relationship between brain metal burden and peripheral neuroinflammation markers in WD.
methodsWe conducted a cross-sectional study involving 89 participants, including patients with WD (n = 63), asymptomatic ATP7B heterozygous carriers (n = 12), and age/sex-matched controls (n = 14). Brain metal burden was assessed using quantitative susceptibility mapping (QSM) MRI. Plasma glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) levels were measured. Clinical severity was evaluated using the mini-Unified Wilson's Disease Rating Scale (UWDRS) and Montreal Cognitive Assessment (MoCA). The influence of copper chelation treatment on biomarker correlations was also examined.
resultsPatients with WD had a significantly higher level of GFAP (p = 0.02) and brain metal burden (p < 0.01) than the control group. Plasma NfL levels were marginally elevated in the WD group (p = 0.07). Notably, elevated plasma GFAP levels were significantly associated with higher UWDRS scores (r = 0.35, p < 0.01) and lower MoCA scores (r = -0.36, p < 0.01). The NfL levels were also correlated with UWDRS (r = 0.58, p < 0.01) and marginally correlated with MoCA (r = -0.32, p = 0.02). The brain magnetic susceptibility value was positively correlated with increased plasma GFAP level, particularly in the putamen (p < 0.001), which was more prominent in WD patients without chelating agent treatment (r = 0.58, p < 0.001). INTERPRETATIONS: Plasma GFAP levels reflect both clinical severity and brain metal accumulation in WD, with this association influenced by copper chelation therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.